Argos Therapeutics


Argos raises $25M for kidney cancer immunotherapy phase 3 study

Immunotherapy company Argos Therapeutics, which last month withdrew plans for a $65 million initial public offering, has now secured a $25 million round of financing to start phase 3 clinical trials on its novel kidney cancer treatment. Forbion Capital led the series D round, joined by fellow existing investors TVM Capital, Lumira Capital, Intersouth Partners, […]


No IPO for immunotherapy company Argos Therapeutics

Immunotherapy company Argos Therapeutics has pulled back on its plans for an initial public offering and leaves it needing to find another way to finance phase 3 clinical trials for its novel kidney cancer treatment. In a letter filed with securities regulators, Argos simply said that it was withdrawing its registration statement “due to market […]


Immunotherapy technology from Argos seeks partner for kidney cancer trials

Immunotherapy company Argos Therapeutics has developed a new technology that could set it apart from other biotechnology cancer treatments — an approach that’s completely personalized to the patient and also costs less. But that’s just the beginning. This personalized medicine platform technology is also being developed to treat other diseases such as HIV. With positive […]